Remdesivir for Treatment of COVID-19 Requiring Oxygen Support: A Cross-Study Comparison from Two Large, Open-Label Studies
Zurich Open Repository and Archive (University of Zurich) · 10.07.2024
DOI: 10.5167/uzh-260967 ↗Kurz gefasst
Fachartikel in der Zeitschrift Zurich Open Repository and Archive (University of Zurich), erschienen am 10.07.2024. Verfasst von Fusco und 35 weiteren Autor:innen.
Abstract (Originalsprache)
Background
Remdesivir, an RNA-polymerase prodrug inhibitor approved for treatment of COVID-19, shortens recovery time and improves clinical outcomes. This prespecified analysis compared remdesivir plus standard-of-care (SOC) with SOC alone in adults hospitalized with COVID-19 requiring oxygen support in the early stage of the pandemic.
Methods
Data for 10-day remdesivir treatment plus SOC from the extension phase of an open-label study (NCT04292899) were compared with real-world, retrospective data on SOC alone (EUPAS34303). Both studies included patients aged ≥18 years hospitalized with SARS-CoV-2 up to 30 May 2020, with oxygen saturation ≤94%, on room air or supplemental oxygen (all forms), and with pulmonary infiltrates. Propensity score weighting was used to balance patient demographics and clinical characteristics across treatment groups. The primary endpoint was time to all-cause mortality or end of study (day 28). Time-to-discharge, with a 10-day landmark to account for duration of remdesivir treatment, was a secondary endpoint.
Results
1974 patients treated with remdesivir plus SOC, and 1426 with SOC alone, were included after weighting. Remdesivir significantly reduced mortality versus SOC (hazard ratio [HR]: 0.46, 95% confidence interval: 0.39–0.54). This association was observed at each oxygen support level, with the lowest HR for patients on low-flow oxygen. Remdesivir significantly increased the likelihood of discharge at day 28 versus SOC in the 10-day landmark analysis (HR: 1.64; 95% confidence interval: 1.43–1.87).
Conclusions
Remdesivir plus early-2020 SOC was associated with a 54% lower mortality risk and shorter hospital stays compared with SOC alone in patients hospitalized with COVID-19 requiring oxygen support. Clinical Trials Registration: ClinicalTrials.gov NCT04292899 and EUPAS34303.
Schlagwörter
Zitieren
APA
Fusco, Dahlene, Malenica, Ivana, Günthard, F, H., Gupta, K, S., Kurbegov, Dax, Balani, Bindu, Olender, Susan, Aberg, A, J., Telep, E, L., Tian, …, & L, R. (2024). Remdesivir for Treatment of COVID-19 Requiring Oxygen Support: A Cross-Study Comparison from Two Large, Open-Label Studies. Zurich Open Repository and Archive (University of Zurich). https://doi.org/10.5167/uzh-260967
Vancouver
Fusco, Dahlene, Malenica, Ivana, Günthard, F H, et al. Remdesivir for Treatment of COVID-19 Requiring Oxygen Support: A Cross-Study Comparison from Two Large, Open-Label Studies. Zurich Open Repository and Archive (University of Zurich). 2024. doi:10.5167/uzh-260967
BibTeX
@article{Fusco2024,
author = {Fusco and Dahlene and Malenica and Ivana and Günthard and F, Huldrych and Gupta and K, Samir and Kurbegov and Dax and Balani and Bindu and Olender and Susan and Aberg and A, Judith and Telep and E, Laura and Tian and Yuan and Blair and Christiana and Wu and George and Haubrich and Richard and Wang and Chen-Yu and Chokkalingam and P, Anand and Osinusi and O, Anu and Wendtner and Clemens-Martin and Gottlieb and L, Robert},
title = {Remdesivir for Treatment of COVID-19 Requiring Oxygen Support: A Cross-Study Comparison from Two Large, Open-Label Studies},
journal = {Zurich Open Repository and Archive (University of Zurich)},
year = {2024},
doi = {10.5167/uzh-260967}
}
EUVIMED